Investor Presentaiton

19 Investor presentation Full year 2022 Appendix Novo Nordisk corporate strategy Diabetes care GLP-1 Insulin Obesity care 20 32 42 49 59 Rare disease 78 Other serious chronic diseases 91 Regional information 109 Financials 141 Sustainability 150

View entire presentation